Zhejiang Huahai Pharmaceutical's (SHA:600521) subsidiary, Huahai Pharmaceutical Europe, received marketing authorization from Germany's drug regulator for apixaban tablets, according to a Tuesday disclosure on the Shanghai bourse.
The drug is used to prevent venous thromboembolic events after elective hip or knee replacement surgery, as well as to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation.